Clinical Trials Logo

Clinical Trial Summary

Beriberi is a potentially fatal disease caused by vitamin B1 (thiamine) deficiency that still occurs in Southeast Asia despite near eradication elsewhere. Mothers with a diet low in thiamine produce thiamine-poor milk, putting their infants at a high risk of developing thiamine deficiency and beriberi. There is also a growing body of evidence suggesting thiamine deficiency not severe enough to cause clinical symptoms may negatively effect cognitive development and functioning of the infant. Since human milk should be the sole source of nutrition for babies during the first six months, maternal thiamine intake must be improved to combat this disease. The investigators' recent study of thiamine-fortified fish sauce in Cambodia showed that fortification could increase maternal and infant thiamine status'. However, centrally produced fish sauce may not reach the poorest communities who make their own fish sauce, and fish sauce is not consumed in all regions where we find thiamine deficiency. Salt, by contrast, is a common condiment in most regions of the world and has proven to be a successful global fortification vehicle for iodine. Suboptimal maternal thiamine intake puts exclusively breastfed infants at risk of low thiamine status, impaired cognitive development, and infantile beriberi, which can be fatal. Thiamine fortification of salt is a potentially low-cost and sustainable means of combating suboptimal thiamine status; however knowledge gaps must be filled before thiamine fortification can proceed. In this study, mothers will consume thiamine supplements in order to model the thiamine dose required to optimize human milk thiamine concentrations for the prevention of beriberi. Other thiamine biomarkers will be assessed, and usual salt intake will be measured. Finally, the investigators will assess the effects of early-life thiamine exposure on infant neuro-cognitive development.


Clinical Trial Description

(see full protocol) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03616288
Study type Interventional
Source Mount Saint Vincent University
Contact
Status Completed
Phase N/A
Start date August 28, 2018
Completion date January 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT03263442 - High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT05663164 - Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS) N/A
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Completed NCT04641104 - The Thiamine Administration After Cardiac Surgery Trial Phase 4
Recruiting NCT06298344 - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease Early Phase 1
Completed NCT03626337 - Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR
Completed NCT05390086 - Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders
Recruiting NCT05480943 - Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Active, not recruiting NCT04453761 - Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass Phase 4
Completed NCT03746106 - The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine Phase 4
Completed NCT03554668 - Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)
Completed NCT01524315 - Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery Phase 4
Completed NCT02464865 - Thiamin Deficiency in Obese Thai Children Phase 4
Completed NCT03228030 - Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial Phase 1